459424-72-7

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
1-Iodo-2,3,4-trifluorobenzene serves as a key intermediate in the production of various pharmaceuticals and agrochemicals. Its unique combination of fluorine and iodine atoms allows for the creation of complex organic molecules with specific biological activities, making it an essential component in the development of new drugs and pesticides.
Used in Liquid Crystal Material Production:
1-Iodo-2,3,4-trifluorobenzene is utilized in the manufacturing process of liquid crystal materials, which are integral to the functioning of electronic displays and other related applications. 1-Iodo-2,3,4-trifluorobenzene's properties contribute to the formation of liquid crystals with desirable characteristics, such as stability and responsiveness to electric fields, enhancing the performance of display technologies.

InChI:InChI=1/C6H2F3I/c7-3-1-2-4(10)6(9)5(3)8/h1-2H

Upstream product

• 1489-53-8 1,2,3-trifluorobenzene 
• 176317-02-5 1-bromo-2,3,4-trifluorobenzene 

Downstream Products

• 203916-59-0 2,3,4-trifluoro-5-iodobenzoic acid 
• 1097626-95-3 2,3,4-trifluoro-5-iodobenzaldehyde 
• 459425-36-6 2,3,4-trifluoro-1,5-diiodobenzene 

Relevant academic research and scientific papers

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)

Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?

An approach and preliminary results for utilizing legacy MEK inhibitors as templates for a reiterative structural based design and synthesis of novel, type III NCKIs (non-classical kinase inhibitors) is described. Evidence is provided that the MEK-pocket

CHROMAN DERIVATIVE AND LIQUID-CRYSTAL COMPOSITION CONTAINING THE COMPOUND

The present invention relates to a liquid crystal compound which has negative dielectric anisotropy and a large absolute value thereof; and a liquid crystal display element which contains the compound as a constituent element and has a negative value of dielectric anisotropy in the vertical alignment mode, IPS, or the like. The liquid-crystal display element has a structure including a pair of substrates and a liquid crystal sandwiched therebetween, and includes at least an alignment control layer, a transparent electrode, and a polarizing plate, in which the liquid crystal includes at least one compound having a partial structure represented by general formula (A): (wherein W1 and W2 each independently represents fluorine, chlorine, -CF3, -CF2H, -OCF3, or -OCF2H) and has negative dielectric anistropy.

Method for producing tetrakis ( fluoroaryl) borate-magnesium compound

Fluoroaryl magnesium halide is reacted with a boron compound so that a molar ratio of the fluoroaryl magnesium halide to the boron compound is not less than 3.0 and not more than 3.7, so as to produce a tetrakis (fluoroaryl) borate·magnesium compound. With this method, there occurs no hydrogen fluoride which corrodes a producing apparatus and requires troublesome waste water treatment.

Synthesis and mesomorphic properties of some liquid crystals with 2,3,5,6-tetrafluorophenylene unit

Nine fluorosubstituted liquid crystals have been synthesized and their mesomorphic properties have been studied by texture observation in a polarizing microscope and confirmed by DSC. They show enantiotropic smectic A and nematic phases. The effect of ter

Extensive halogen scrambling and buttressing effects encountered upon treatment of oligobromoarenes with bases

As a rule, tri-, tetra- and pentahaloarenes readily undergo ortho-lithiation when treated with amide-type bases. However, halogen migration occurs whenever the substrate contains three or more contiguous halogen atoms, provided that at least one of them is bromine or iodine. Dismutation and reduction processes often take place concomitantly. In this manner, a variety of organometallic intermediates may be formed, the driving force always being a decrease in basicity. When no such energy gain can be achieved, a sterically crowded substrate may just turn out to be inert; this was found to be the case with 1,5-dibromo-3-fluoro-2-(trimethylsilyl)benzene, 1,5-dibromo-3-fluoro-2,4-bis(trimethylsilyl)benzene, and 1,5-dibromo-3-fluoro-2,4-diiodobenzene. Buttressing effects are apparently strong enough to prevent expedient deprotonation of those substrates.

Benzene derivatives and a liquid-crystalline medium

The invention relates to novel benzene derivatives of the formula I STR1 in which n is 0, 1, 2, 3, 4, 5, 6 or 7, Q is --O--, --CH=CH-- or a single bond, r is 0, 1, 2, 3, 4 or 5, s is 0, 1 or 2, X is F, Cl, OCHF2 or CF3, L is H or F, and A is STR2 Z, Z-Ar, Ar-Z, Z-Cyc in which Z is a single bond, --(CH2)2 -- or --(CH2)4 --, Ar is 1,4-phenylene or biphenyl-4,4'-diyl and Cyc is trans-1,4-cyclohexylene.